Boosman, René J. http://orcid.org/0000-0002-6399-2604
Crombag, Marie-Rose B. S.
van Erp, Nielka P.
Beijnen, Jos H.
Steeghs, Neeltje
Huitema, Alwin D. R.
Clinical trials referenced in this document:
Documents that mention this clinical trial
Article History
Received: 27 December 2021
Accepted: 1 April 2022
First Online: 15 April 2022
Declarations
:
: R.J. Boosman, M.B.S. Crombag and A.D.R. Huitema declare that they have no conflict of interest. N.P. van Erp received research grant from Astellas, Janssen-Cilag and Ipsen. J.H. Beijnen has received payment for expert testimony for Hoyng Tokh Monegier (paid to their institution), is a part-time employee and (in)direct stockholder of Modra Pharmaceuticals and (jointly) holds a patent on oral taxane formulations, which are clinically developed by Modra Pharmaceuticals. Modra Pharmaceuticals is a small spin-off company of the Netherlands Cancer Institute. All of these conflicts are outside of the submitted work. N. Steeghs provided consultation or attended advisory boards for Boehringer Ingelheim, Ellipses Pharma. N Steeghs received research grants for the institute from AB Science, Abbvie, Actuate Therapeutics, ADCtherapeutics, Amgen, Array, Ascendis Pharma, Astex, AstraZeneca, Bayer, Blueprint Medicines, Boehringer Ingelheim, BridgeBio, Bristol-Myers Squibb, Cantargia, Celgene, CellCentric, Cresecendo, Cytovation, Deciphera, Eli Lilly, Exelixis, Genentech, Genmab, Gilead, GlaxoSmithKline, Incyte, InteRNA, Janssen/Johnson&Johnson, Kinate, Merck, Merck Sharp & Dohme, Merus, Molecular Partners, Novartis, Numab, Pfizer, Pierre Fabre, Regeneron, Roche, Sanofi, Seattle Genetics, Servier, Taiho, Takeda (outside the submitted work).